Rallybio Quarterly Cash Flow Statement
NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.47-0.05 (-0.32%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Rallybio free cash flow
In the quarter ended Sep 30, 2026, Rallybio generated -$2.3 million of operating cash flow. That left free cash flow of -$2.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Rallybio cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -2.73M | 43.66M | -8.28M | -5.85M | 16.02M | -9.70M | -9.44M | -11.04M | -11.47M | -16.24M | -19.03M | -20.24M |
| Net Income growth (YoY) | -117.01% | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 0 | 2.00K | 3.00K | 3.00K | 35.00K | 26.00K | 28.00K | 30.00K | 32.00K | 34.00K | 35.00K | 36.00K |
| Stock-Based Compensation | 405.00K | 424.00K | 613.00K | 774.00K | 1.05M | 1.61M | 1.88M | 1.96M | 2.03M | 1.92M | 2.09M | 2.55M |
| Change in Working Capital | -498.00K | 1.81M | -265.00K | 493.00K | -1.19M | -450.00K | -3.05M | -925.00K | -4.43M | 3.80M | 1.30M | 6.06M |
| Operating Cash Flow | -2.28M | 45.92M | -7.98M | -4.68M | -6.55M | -8.38M | -10.21M | -9.86M | -13.54M | -10.42M | -15.46M | -11.64M |
| Capital Expenditures | — | — | — | — | — | — | — | — | — | — | — | -12.00K |
| Investing Cash Flow | 0 | 5.50M | 17.90M | 3.92M | 29.23M | 3.04M | 11.08M | -1.57M | 22.20M | 2.60M | 10.26M | 16.91M |
| Financing Cash Flow | 120.00K | 131.00K | 3.00K | 6.00K | 0 | 10.00K | 0 | 18.00K | -11.00K | 5.19M | 0 | 72.00K |
| Net Change in Cash | -2.16M | 51.55M | 9.93M | -748.00K | 22.68M | -5.33M | 876.00K | -11.42M | 8.65M | -2.63M | -5.19M | 5.34M |
| Free Cash Flow | -2.28M | 45.92M | -7.98M | -4.68M | -6.55M | -8.38M | -10.21M | -9.86M | -13.54M | -10.42M | -15.46M | -11.66M |
This table shows 12 quarterly periods of Rallybio's cash flow statement, from Q3 2026 back to Q4 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RLYB's reporting calendar. What is a cash flow statement?